The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147, a ...

Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today ...

Abdera Therapeutics Inc.’s ABD-147 has been granted U.S. orphan drug designation for the treatment of neuroendocrine carcinoma. ABD-147 is a next-generation precision radiopharmaceutical biologic ...

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small ...

If you're a young person (or a parent of one), you may be thinking some big thoughts about your future. Am I going to go to ...

Who are the top ancient Greek philosophers, and what are their contributions to philosophy and modern life? Read on to ...

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, ch ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Acral Lentiginous Melanoma.

Anne Stevens, VP of Business Development at AbCellera was elected as Chair, Ali Ardakani, Founder and Managing Director of ...